Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), a much milder form of the disease where the age of onset can sometimes be as late as the third or fourth decade of life, are caused by mutations in the same X-linked gene, a 14 kilobase (kb) transcript which is spread over more than 2 megabases of the human X chromosome. The corresponding protein, dystrophin, has a relative molecular mass of 400,000. Most mutations causing DMD and BMD are deletions and deletions associated with both phenotypes are observed throughout the gene sequence. This observation led to the suggestion that DMD patients possess deletions that disrupt the reading frame of the protein, whereas BMD patients have deletions that retain the translational reading frame and enable the muscle cells to produce altered dystrophin products. This theory is supported by immunoblotting studies, which show that DMD patients lack dystrophin in their muscle cells or that dystrophin is present at very low levels, whereas BMD patients produce a protein with reduced abundance or abnormal size. Here we describe a deletion of the dystrophin gene in a family segregating for very mild BMD, one member of which was still ambulant at age 61 years, which removes a central part of the dystrophin gene encompassing 5,106 base pairs of coding sequence, almost half the coding information. Immunological analysis of muscle from one of the patients demonstrates that this mutation results in the production of a truncated polypeptide localized correctly in the muscle cell. These results are particularly significant in the context of gene therapy which, if it is ever envisaged, would be facilitated by the replacement of the very large dystrophin gene with a more manipulatable mini-gene construct.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, many shortened versions of the Duchenne muscular dystrophy gene (DMD; 2.3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the micro-dystrophin for which was reported a milder clinical phenotype [183,184].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [184]
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Self-citationThe Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle
Zubrzycka-Gaarn, E. E., Bulman, D. E., Karpati, G., Burghes, A. H. M., Belfall, B., Klamut, H. J., Talbot, J., Hodges, R. S., Ray, P. N., & Worton, R. G. (1988) · Nature · doi:10.1038/333466a0 · Cited by 658
Self-citationAn autosomal transcript in skeletal muscle with homology to dystrophin
Love, D. R., Hill, D. F., Dickson, G., Spurr, N. K., Byth, B. C., Marsden, R. F., Walsh, F. S., Edwards, Y. H., & Davies, K. E. (1989) · Nature · doi:10.1038/339055a0 · Cited by 494
Self-citationAnalysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy
co-authors, & Kunkel, L. M. (1986) · Nature · doi:10.1038/322073a0 · Cited by 474
Immunoelectron microscopic localization of dystrophin in myofibres
Watkins, S. C., Hoffman, E. P., Slayter, H. S., & Kunkel, L. M. (1988) · Nature · doi:10.1038/333863a0 · Cited by 449
Davies, K. E., Pearson, P. L., Harper, P. S., Murray, J. M., O'Brien, T., Sarfarazi, M., & Williamson, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.8.2303 · Cited by 397
Self-citation
Research works printed but not linked: 5
- Darras, B. T. & Francke, U. Am. J. hum. Genet. 43, 612–619 (1988).
- Love, D. R. & Davies, K. E. Molec biol. Med. 6, 7–17 (1989).
- Davies, K. E. et al. J. Med. Genet. 99, 99 (1987).
- Koenig, M., et al. Am. J. hum. Genet. 45, 498–506 (1989).
- Den Dunnen, J. T. Am. J. hum. Genet, in the press.
Cited by
Items 201–300 of 617
Designing Heart Performance by Gene Transfer
Davis, J., Westfall, M. V., Townsend, D., Blankinship, M. J., Herron, T. J., Guerrero‐Serna, G., Wang, W., Devaney, E. J., & Metzger, J. M. (2008) · Physiological Reviews · doi:10.1152/physrev.00039.2007 · Cited by 63
“Significantly truncated dystrophin molecules that retain functionality were first described in patients with Becker muscular dystrophy (212), and additional studies mapped the critical domains required for dystrophin function (144, 329, 687, 718, 777).”
BackgroundSkipping Multiple Exons of Dystrophin Transcripts Using Cocktail Antisense Oligonucleotides
Echigoya, Y., & Yokota, T. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0451 · Cited by 62
“Dystrophin can retain significant functionality even when it is missing large parts (England et al., 1990; Harper et al., 2002; Roberts et al., 2002; Sakamoto et al., 2002; Shin et al., 2012).”
Gene therapy for Duchenne muscular dystrophy
Ramos, J. N., & Chamberlain, J. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1088780 · Cited by 69
“One BMD patient with an in-frame deletion of exons 17 -- 48 has captured much attention for remaining ambulatory into his 70s [10].”
BackgroundThe progress of AAV-mediated gene therapy in neuromuscular disorders
Aguti, S., Malerba, A., & Zhou, H. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1479739 · Cited by 67
“The rationale behind the approach of introducing a truncated but functional dystrophin product for DMD derives from the observation that Becker patients with short but in frame dystrophin genes can present a mild dystrophic phenotype [19].”
BackgroundProgress Toward Human Gene Therapy
Morsy, M. (1993) · JAMA · doi:10.1001/jama.1993.03510190094033 · Cited by 57
Marrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56
“This idea was first put forward by the Davies lab upon discovery of the Δ17–48 mini-dystrophin natural protein variant in 1990 [67].”
BackgroundDuchenne muscular dystrophy: an updated review of common available therapies
Salmaninejad, A., Valilou, S. F., Bayat, H., Ebadi, N., Daraei, A., Yousefi, M., Nesaei, A., & Mojarrad, M. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1430694 · Cited by 61
“including gross deletions and duplications which may lead to a frameshift (70%) and rarely point mutations (30%) that cause abnormal domain function of dystrophin protein [4].”
The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
Guiraud, S., Edwards, B., Babbs, A., Squire, S. E., Berg, A., Moir, L., Wood, M. J. A., & Davies, K. E. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz049 · Cited by 56
Self-citationFunctional significance of dystrophin positive fibres in Duchenne muscular dystrophy.
Nicholson, L. V. B., Johnson, M. A., Bushby, K. M. D., & Gardner‐Medwin, D. (1993) · Archives of Disease in Childhood · doi:10.1136/adc.68.5.632 · Cited by 56
“23 The DNA is transcribed into RNA with the protein coding sequence contained in about 79 segments or exons, and the RNA is translated into protein.”
Self-citationEvolutionary conservation of the dystrophin central rod domain
Sherratt, T. G., Vulliamy, T., & Strong, P. N. (1992) · Biochemical Journal · doi:10.1042/bj2870755 · Cited by 56
Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies
Benedetti, S., Hoshiya, H., & Tedesco, F. S. (2013) · FEBS Journal · doi:10.1111/febs.12178 · Cited by 66
Duchenne muscular dystrophy gene therapy: Lost in translation?
Duan, D. (2011) · Research and Reports in Biology · doi:10.2147/rrb.s13463 · Cited by 68
Gene Therapy for Duchenne Muscular Dystrophy: Expectations and Challenges
Rodino‐Klapac, L. R., Chicoine, L. G., Kaspar, B. K., & Mendell, J. R. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1236 · Cited by 73
“The seminal example involves a 61-year-old ambulatory patient with Becker dystrophy with a rod domain deletion (exons 1748), equivalent to almost half (48%) of the coding region ofdystrophin.(35) Suchfindingsencouragedasystematicstudy in dystrophin-deficient (mdx) mice to find the optimal complementary DNA that would…”
BackgroundImpending therapies for Duchenne muscular dystrophy
Partridge, T. A. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834aa3f1 · Cited by 58
Personalized gene and cell therapy for Duchenne Muscular Dystrophy
Barthélémy, F., & Wein, N. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.06.009 · Cited by 59
Gene therapy to treat cardiac arrhythmias
Bongianino, R., & Priori, S. G. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.61 · Cited by 57
Angelini, C. I., Fanin, M., Pegoraro, E., Freda, M. P., Cadaldini, M., & Martinello, F. (1994) · Neuromuscular Disorders · doi:10.1016/0960-8966(94)90071-x · Cited by 54
Vainzof, M., Zubrzycka‐Gaarn, E. E., Rapaport, D., Passos‐Bueno, M. R., Pavanello, R. C. M., Pavanello‐Filho, I., & Zatz, M. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90038-9 · Cited by 54
Self-citationMuscular dystrophy with truncated dystrophin in a family of Japanese Spitz dogs
Jones, B. R., Brennan, S. F., Mooney, C. T., Callanan, J. J., McAllister, H., Guo, L. T., Martin, P. T., Engvall, E., & Shelton, G. D. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.09.002 · Cited by 59
“It has been shown that a large in-frame deletion in the central rod domain results in Becker muscular dystrophy (BMD), an allelic, milder form of Duchenne muscular dystrophy (DMD) [3].”
BackgroundX‐Linked Dilated Cardiomyopathy: Novel Mutation of the Dystrophin Gene
Franz, W. M., Cremer, M., Herrmann, R., Grünig, E., FOGEL, W., Scheffold, T., Goebel, H. H., Kircheisen, R., Kübler, W., Voït, T., et al. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb17457.x · Cited by 57
Karpati, G., & Acsádi, G. (1993) · Muscle & Nerve · doi:10.1002/mus.880161102 · Cited by 61
Interplay between DMD Point Mutations and Splicing Signals in Dystrophinopathy Phenotypes
Juan‐Mateu, J., González‐Quereda, L., Rodríguez, M. J., Verdura, E., Lázaro, K., Jou, C., Nascimento, A., Jimenez-Mallebrera, C., Colomer, J., Monges, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059916 · Cited by 52
“Some parts of the central rod-domain can be truncated with minimal impact on protein function [6].”
BackgroundMolecular Extensibility of Mini-dystrophins and a Dystrophin Rod Construct
Bhasin, N., Law, R., Liao, G. P., Safer, D., Ellmer, J., Discher, B. M., Sweeney, H. L., & Discher, D. E. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.064 · Cited by 52
Schmitz, F., & Drenckhahn, D. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00047-6 · Cited by 66
Love, D. R., Flint, T. J., Genet, S., Middleton-Price, H. R., & Davies, K. E. (1991) · Journal of Medical Genetics · doi:10.1136/jmg.28.12.860 · Cited by 59
Self-citationMatsumura, K., Burghes, A. H. M., Mora, M., Tomé, F. M. S., Morandi, L. O., Cornello, F., Leturcq, F., Jeanpierre, M., Jc, K., & Reinert, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116989 · Cited by 51
Cell and Gene Therapy in Duchenne Muscular Dystrophy
Morgan, J. E. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.2-165 · Cited by 51
Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies
Lindley, S. R., Subbaiah, K. C. V., Priyanka, F., Poosala, P., Ma, Y., Jalinous, L., West, J. A., Richardson, W. A., Thomas, T. N., & Anderson, D. M. (2024) · Science · doi:10.1126/science.adp8179 · Cited by 58
242 Breakpoints in the 200-kb deletion-prone P20 region of the DMD gene are widely spread
Blonden, L. A. J., Grootscholten, P. M., den Dunnen, J. T., Bakker, E., Abbs, S. J., Bobrow, M., Boehm, C. D., Broeckhoven, C. V., Baumbach, L. L., Chamberlain, J. S., et al. (1991) · Genomics · doi:10.1016/0888-7543(91)90445-k · Cited by 58
Cardiac Consequences to Skeletal Muscle-Centric Therapeutics for Duchenne Muscular Dystrophy
Townsend, D., Yasuda, S., Chamberlain, J. S., & Metzger, J. M. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.04.006 · Cited by 49
“The realization that truncation of dystrophin could result in highly functional dystrophin molecules stems from the molecular characterization of Becker muscular dystrophy patients (BMD) (England et al. 1990).”
BackgroundImmune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice
Braun, S., Thioudellet, C., Rodriguez, P., Ali-Hadji, D., Perraud, F., Accart, N., Balloul, J.-M., Halluard, C., Acres, B., Cavallini, B., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301261 · Cited by 49
The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy
Guiraud, S., Roblin, D., & Kay, D. E. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1438261 · Cited by 48
“300376) [7] leads to costamere perturbation, sarcolemma fragility, and subsequent chronic inflammation associated with a failed regenera-”
BackgroundShin, J.-H., Yue, Y., Srivastava, A., Smith, B., Lai, Y., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.147 · Cited by 47
“It was noted that an in-frame deletion of 46% of the dystrophin gene was associated with very mild disease (England et al., 1990).”
BackgroundSystemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Zhou, Y., Zhang, C., Xiao, W., Herzog, R. W., & Han, R. (2024) · Nature Communications · doi:10.1038/s41467-024-50569-6 · Cited by 51
“Early studies found that patientscarryingalargeinternaldeletionofthe DMD genedevelopeda milder form of the disease, known as Becker muscular dystrophy (BMD), due to the expression of truncated yet partially functional dystrophin proteins 11 .”
Cazzella, V., Martone, J., Pinnarò, C., Santini, T., Twayana, S., Sthandier, O., D’Amico, A., Ricotti, V., Bertini, E., Muntoni, F., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.178 · Cited by 46
Genetic Therapeutic Approaches for Duchenne Muscular Dystrophy
Foster, H., Popplewell, L. J., & Dickson, G. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.099 · Cited by 52
“The development of mini-or micro-dystrophin genes is based on observations in patients with Becker muscular dystrophy (BMD), who despite often having large deletions, present with a mild phenotype or can even be asymptomatic (England et al ., 1990; Matsumura et al ., 1994; Beroud et al ., 2007).”
Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing
Hanson, B., Wood, M. J. A., & Roberts, T. C. (2021) · RNA Biology · doi:10.1080/15476286.2021.1874161 · Cited by 54
“in some rare cases BMD patients are effectively asymptomatic [30,31].”
BackgroundDubowitz, V. (1992) · Postgraduate Medical Journal · doi:10.1136/pgmj.68.801.500 · Cited by 47
Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable
Harper, S. Q., Crawford, R. W., DelloRusso, C., & Chamberlain, J. S. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.16.1807 · Cited by 51
Are cysteine-rich and COOH-terminal domains of dystrophin critical for sarcolemmal localization?
Récan, D., Chafey, P., Leturcq, F., Hugnot, J., Vincent, N., Tomé, F. M. S., Collin, H., Simon, D., Czernichow, P., & Nicholson, L. V. B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115640 · Cited by 46
“(22) is normally localized at the sarcolemma.”
Self-citationGene Therapy for Muscular Dystrophy: Moving the Field Forward
Al-Zaidy, S. A., Rodino‐Klapac, L. R., & Mendell, J. R. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.08.002 · Cited by 47
“The concept of miniature forms of the dystrophin gene that could translate into a functional protein came from the clinical observation of a BMD patient who remained ambulatory until the 7th decade despite a deletion in 46% of his DMD gene [34].”
BackgroundEvolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
D'Ambrosio, E. S., & Mendell, J. R. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01423-y · Cited by 49
“A major contribution is the well-known report that ambulation with mild dystrophinopathy persisted beyond 60 years of age [59].”
BackgroundDunant, P., Larochelle, N., Thirion, C., Stucka, R., Ursu, D., Petrof, B. J., Wolf, E., & Lochmüller, H. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00129-1 · Cited by 50
Human dystrophin gene transfer: production and expression of a functional recombinant DNA-based gene
Dickson, G., Love, D. R., Davies, K., Wells, K., Piper, T. A., & Walsh, F. S. (1991) · Human Genetics · doi:10.1007/bf00204929 · Cited by 43
“…Karpati 1991), and secondly, the direct introduction of a functional recombinant-DNA-based gene encoding human dystrophin using viral-based transmission vectors or physical injection of pure DNA (Feigner and Rhodes 1991; Lee et al. 1991; England et al. 1990; Wolff et al. 1990; Friedmann 1989).”
BackgroundMethodSelf-citationDystrophin or a “related protein” in Duchenne muscular dystrophy?
Nicholson, L. V. B., Johnson, M. A., Davison, K., O'Donnell, E., Falkous, G., Barron, M. J., & Harris, J. B. (1992) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1992.tb08046.x · Cited by 44
Self-citationHagiwara, Y., Nishio, H., Kitoh, Y., Takeshima, Y., Narita, N., Wada, H., Yokoyama, M., Nakamura, H., & Matsuo, M. (1994) · PubMed · Cited by 52
Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy
Hart, C. C., Lee, Y. I., Xie, J., Gao, G., Lin, B. L., Hammers, D. W., & Sweeney, H. L. (2024) · JCI Insight · doi:10.1172/jci.insight.165869 · Cited by 49
“The potential to modify a severe DMD disease using a truncated dystrophin molecule was initially suggested by the existence of mildly progressing patients with BMD who express mutant dystrophin proteins missing most of the rod domain (55, 56).”
BackgroundEndonucleases: tools to correct the dystrophin gene
Rousseau, J., Chapdelaine, P., Boisvert, S., de Almeida, L. P., Corbeil, J., Montpetit, A., & Tremblay, J. P. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1611 · Cited by 51
“subjects or to Becker muscular dystrophy with a milder phenotype [1–3].”
BackgroundTherapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
Mbakam, C. H., Lamothe, G., & Tremblay, J. P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.859930 · Cited by 49
“In another case, a 61 years old man had 46% of his DMD gene deleted, however, this gene was still capable of synthesizing a functional truncated dystrophin (17).”
BackgroundMadden, H. R., Fletcher, S., Davis, M. R., & Wilton, S. D. (2008) · Human Mutation · doi:10.1002/humu.20806 · Cited by 47
“This is evidenced in individuals with the milder allelic disorder, Becker muscular dystrophy (BMD) [Beggs et al., 1991; England et al., 1990; Heald et al., 1994].”
Moisset, P.-A., Skuk, D., Asselin, I., Goulet, M., Roy, B., Karpati, G., & Tremblay, J. P. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8739 · Cited by 42
Morandi, L. O., Mora, M., Gussoni, E., Tedeschi, S., & Cornelio, F. (1990) · Annals of Neurology · doi:10.1002/ana.410280512 · Cited by 42
Incitti, T., Angelis, F. G. D., Cazzella, V., Sthandier, O., Pinnarò, C., Legnini, I., & Bozzoni, I. (2010) · Molecular Therapy · doi:10.1038/mt.2010.123 · Cited by 47
Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD
Guiraud, S., Edwards, B., Squire, S. E., Moir, L., Berg, A., Babbs, A., Ramadan, N., Wood, M. J. A., & Davies, K. E. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy353 · Cited by 40
“The absence or reduction of dystrophin in the milder Becker muscular dystrophy (BMD, MIM #300376) (8) leads to sarcolemma”
BackgroundSelf-citationVerheul, R. C., van Deutekom, J. C. T., & Datson, N. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162467 · Cited by 44
Fanin, M., Freda, M. P., Vitiello, L., Danieli, G. A., Pegoraro, E., & Angelini, C. I. (1996) · Muscle & Nerve · doi:10.1002/mus.880190902 · Cited by 40
Nguyen, T. M., Ginjaar, I. B., van Ommen, G. B., & Morris, G. E. (1992) · Biochemical Journal · doi:10.1042/bj2880663 · Cited by 40
AAV-directed muscular dystrophy gene therapy
Tang, Y. M., Cummins, J. H., Huard, J., & Wang, B. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003604690 · Cited by 50
“exhibits large in-frame deletions of the dystrophin gene in the central rod domain (triple-helical central rod repeats); however, BMD patients display only slight phenotypic symptoms [103], suggesting that a major portion of the rod domain is dispensable.”
BackgroundImmunological hurdles in the path to gene therapy for Duchenne muscular dystrophy
Wells, D. J., Ferrer, A., & Wells, K. E. (2002) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940200515x · Cited by 42
Induction of revertant fibres in the mdx mouse using antisense oligonucleotides
Fall, A., Johnsen, R. D., Honeyman, K., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-4-3 · Cited by 38
AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects
Chwalenia, K., Feng, V.-Y., Hemmer, N., Friedrichsen, H. J., Vorobieva, I., Wood, M. J. A., & Roberts, T. C. (2025) · Gene Therapy · doi:10.1038/s41434-025-00561-6 · Cited by 44
“The severity varies widely between individuals and ranges from effectively asymptomatic [43, 44] to DMD-like phenotypes [45].”
Gee, P., Xu, H., & Hotta, A. (2017) · Stem Cells International · doi:10.1155/2017/8765154 · Cited by 39
“In fact, BMD patients who lack more than half of the dystrophin protein coding sequence in the rod domain have been documented [21, 22].”
BackgroundInfluentialUpdate on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers
Datta, N., & Ghosh, P. S. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01034-6 · Cited by 38
Deletion of exon 16 of the dystrophin gene is not associated with disease
Schwartz, M., Dunø, M., Palle, A. L., Krag, T. O. B., & Vissing, J. (2007) · Human Mutation · doi:10.1002/humu.9477 · Cited by 42
“The presence/ absence of each exon was analyzed on an ABI310 genetic analyzer (Applied Biosystems, Foster City, CA; http://europe.appliedbiosystems.com) These conditions were also used as an approach for detection female carriers from families, in which a deletion has been detected in a DMD/BMD relative, using the rat…”
BackgroundInfluentialMuscle Structure Influences Utrophin Expression in mdx Mice
Banks, G. B., Combs, A. C., Odom, G. L., Bloch, R. J., & Chamberlain, J. S. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004431 · Cited by 44
“expressing truncated dystrophins can have a mild phenotype without restoring nNOS to the sarcolemma [12,107].”
Nicholson, L. V. B., Johnson, M. A., Bushby, K. M. D., Gardner‐Medwin, D., Curtis, A., Ginjaar, I. B., den Dunnen, J. T., Welch, J. L., Butler, T. J., & Bakker, E. (1993) · Journal of Medical Genetics · doi:10.1136/jmg.30.9.745 · Cited by 37
Self-citationGiant dystrophin deletion associated with congenital cataract and mild muscular dystrophy
Massimiliano Mirabella, A., Galluzzi, G., Manfredi, G., Bertini, E., Ricci, E., Leo, R. D., Tonali, P. A., & Servidei, S. (1998) · Neurology · doi:10.1212/wnl.51.2.592 · Cited by 37
Legardinier, S., Legrand, B., Raguénès-Nicol, C., Bondon, A., Hardy, S., Tascon, C., Rumeur, É. L., & Hubert, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805846200 · Cited by 38
Adenovirus-mediated gene transfer into striated muscles
Acsádi, G., Jani, A., & Massie, B. (1995) · Journal of Molecular Medicine · doi:10.1007/bf00188137 · Cited by 42
The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy
Bengtsson, N. E., Tasfaout, H., & Chamberlain, J. S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.065 · Cited by 41
“14 Unfortunately, gene expression was found to be transient due to cellular immune responses that were elicited by residual, low-level Ad protein expression.”
Muthu, M., Richardson, K. A., & Sutherland‐Smith, A. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040066 · Cited by 35
“The importance of individual spectrin repeat domains for overall Dys function was initially assumed to be low owing to the observation that in-frame deletion of repeats 4–19, (nearly half of Dys) gave rise to a mild BMD phenotype [11].”
BackgroundWells, D. J., & Wells, K. E. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00077-9 · Cited by 35
6 Dystrophin, Its Gene, and the Dystrophinopathies
Roberts, R. G. (1995) · Advances in genetics · doi:10.1016/s0065-2660(08)60334-x · Cited by 36
Ozawa, E. (2010) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.86.798 · Cited by 40
Mollanoori, H., Rahmati, Y., Hassani, B., Havasi Mehr, M., & Teimourian, S. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.007 · Cited by 32
“These mutations are associated with much milder symptoms of disease which is termed BMD.(22) By providing a rational justification, these observations led to the development of approaches of creating a dystrophin protein similar to the dystrophin expressed in BMD patient which has deletions but still retain ORF.”
BackgroundMethodTherapeutic Approaches for Duchenne Muscular Dystrophy: Old and New
Mackenzie, S., Nicolau, S., Connolly, A. M., & Mendell, J. R. (2021) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2021.100877 · Cited by 37
Quenneville, S., Chapdelaine, P., Rousseau, J., & Tremblay, J. P. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302887 · Cited by 39
Zhang, K., Yang, X., Lin, G., Han, Y., & Li, J. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.01.014 · Cited by 38
Therapy of Genetic Disorders: Novel Therapies for Duchenne Muscular Dystrophy
Seto, J. T., Bengtsson, N. E., & Chamberlain, J. S. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0044-x · Cited by 41
“[3] lent proof of principle that restoring some functional dystrophin expression can ameliorate the disease severity of DMD.”
BackgroundMicrodystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials
Chamberlain, J. S., Robb, M. A., Braun, S., Brown, K. J., Danos, O., Ganot, A., Gonzalez‐Alegre, P., Hunter, N., McDonald, C. M., Morris, C. A., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.190 · Cited by 33
“Subsequently, two groups generated additional transgenic mdx mice expressing either fulllength or internally truncated dystrophin, the latter of which was based on a BMD patient with a 1 MB deletion (of exons 17–48) who remained ambulatory until his death in his late 70s.(31) Very mild phenotypes have been associated…”
BackgroundDeol, J. R., Danialou, G., Larochelle, N., Bourget, M., Moon, J.-S., Liu, A., Gilbert, R., Petrof, B. J., Nalbantoglu, J. N., & Karpati, G. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300260 · Cited by 38
Adeno-associated Virus and AAV Vectors for Gene Delivery
Carter, B. J., Burstein, H., & Peluso, R. W. (2000) · CRC Press eBooks · doi:10.1201/9781420002126-12 · Cited by 34
Matsumura, K., Nonaka, I., Tomé, F. M. S., Arahata, K., Collin, H., Leturcq, F., Récan, D., Jc, K., Fardeau, M., & Campbell, K. P. (1993) · Europe PMC (PubMed Central) · Cited by 33
Merosin and congenital muscular dystrophy
Miyagoe‐Suzuki, Y., Nakagawa, M. M., & Takeda, S. (2000) · Microscopy Research and Technique · doi:10.1002/(sici)1097-0029(20000201/15)48:3/4<181::aid-jemt6>3.0.co;2-q · Cited by 119
Szwec, S., Kapłucha, Z., Chamberlain, J. S., & Konieczny, P. (2023) · BioDrugs · doi:10.1007/s40259-023-00632-3 · Cited by 38
“A solution to this problem emerged when one of the BMD patients had mild disease symptoms, walking on his own at 61 years of age, despite the extensive deletion of about 46% in the DMD gene [89].”
BackgroundTherapeutic Strategies for Duchenne and Becker Dystrophies
Voisin, V., & de la Porte, S. (2004) · International review of cytology · doi:10.1016/s0074-7696(04)40001-1 · Cited by 36
Fassati, A., Wells, D. J., Serpente, P., Walsh, F. S., Brown, S., Strong, P. N., & Dickson, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119573 · Cited by 36
“This indicated that the vast majority of dys(1) fibers detected with P6 antibody were expressing the Becker-type human dystrophin cDNA, for the region recognized by mAb MANDYS1 is deleted in the 229-kD Becker minidystrophin (8, 29).”
BackgroundMethodGenome editing for Duchenne muscular dystrophy: a glimpse of the future?
Kupatt, C., Windisch, A., Moretti, A., Wolf, E., Wurst, W., & Walter, M. C. (2021) · Gene Therapy · doi:10.1038/s41434-021-00222-4 · Cited by 37
Nicholson, L. V. B., Bushby, K. M. D., Johnson, M. A., den Dunnen, J. T., Ginjaar, I. B., & van Ommen, G. B. (1992) · Journal of Medical Genetics · doi:10.1136/jmg.29.12.892 · Cited by 34
Self-citationDystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype
Morandi, L. O., Mora, M., Confalonieri, V., Barresi, R., Blasi, C. D., Brugnoni, R., Bernasconi, P., Mantegazza, R., Dworzak, F., Antozzi, C. G., et al. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00147-t · Cited by 33
Wakayama, Y., Jimi, T., Takeda, A., Misugi, N., Kumagai, T., Miyake, S., & Shibuya, S. (1990) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(90)90222-9 · Cited by 31
Functional EGFP–dystrophin fusion proteins for gene therapy vector development
Chapdelaine, P., Moisset, P.-A., Campeau, P. M., Asselin, I., Vilquin, J., & Tremblay, J. P. (2000) · Protein Engineering Design and Selection · doi:10.1093/protein/13.9.611 · Cited by 31
Nguyen, T. M., & Morris, G. E. (1993) · Europe PMC (PubMed Central) · Cited by 30
Ikezawa, M., Cao, B., Qu, Z., Peng, H., Xiao, X., Pruchnic, R., Kimura, S., Miike, T., & Huard, J. (2003) · Human Gene Therapy · doi:10.1089/104303403322495043 · Cited by 30
“Observation of a number of mildly affected patients with BMD bearing large in-frame deletions—including one patient displaying an absence of over 40% of the central rod domain of the dystrophin gene—suggests that a functional mini-dystrophin gene could alleviate the DMD phenotype (England et al., 1990).”
Vissing, H., D’Alessio, M., Lee, B., Ramirez, F., Byers, P. H., Steinmann, B. U., & Superti‐Furga, A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)67778-1 · Cited by 31
Wang, J., Forst, J., Schröder, S. A., & Schröder, J. M. (1999) · Neuromuscular Disorders · doi:10.1016/s0960-8966(98)00114-x · Cited by 29
“It is confirmed that the clinical phenotype depends more on whether or not the deletion disrupts the nucleotide reading frame [44–48].”
BackgroundDrug Discovery of Therapies for Duchenne Muscular Dystrophy
Blat, Y., & Blat, S. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115586535 · Cited by 34
“In fact, an in-frame deletion as large as 46% of the dystrophin protein, found in a BMD patient, allows partial maintenance of dystrophin function.(11) The observation that large deletions in the spectrin-repeats domain lead to only partial loss of function is the basis for some of the most promising therapies that ar…”
BackgroundMicro-dystrophin Genes Bring Hope of an Effective Therapy for Duchenne Muscular Dystrophy
Davies, K. E., & Guiraud, S. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.019 · Cited by 30
Self-citationStraková, J., Dean, J. D., Sharpe, K. M., Vetter, T. A., Odom, G. L., & Townsend, D. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.08.013 · Cited by 30
“Dystrophin's domain structure is well characterized and several highly functional μ-dystrophins have been generated and evaluated [29, 48-51].”
MethodUtility of MLPA in mutation analysis and carrier detection for Duchenne muscular dystrophy
Phadke, S. R., Dalal, A. B., Verma, P. K., & Mittal, B. (2012) · Indian journal of human genetics · doi:10.4103/0971-6866.96667 · Cited by 28
“Large in-frame deletions removing up to 35 exons in the central rod domain have been described for mild BMD.[20-23] Reading-frame checker ver1.”
Metadata
- Authors
- England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E.
- Affiliations
- John Radcliffe Hospital (GB)
- Hospital for Sick Children (CA)
- Venue
- Nature
- Published
- 1990-01
- Volume
- 343
- Issue
- 6254
- Pages
- 180-182
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2058807250
- Cited by
- 623
- References
- 25
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 16 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 23 · 2014: 16 · 2013: 17 · 2012: 22
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- Becker muscular dystrophy, Duchenne muscular dystrophy, dystrophin gene deletion, dystrophin, X-linked inheritance, reading frame, gene therapy
- MeSH terms
- Chromosome Deletion, Exons, Female, Genes, Humans, Male, Middle Aged, Muscle Proteins, Muscles, Muscular Dystrophies, Nucleic Acid Hybridization, Pedigree, Protein Conformation, Reference Values, Blotting, Western, Restriction Mapping, Dystrophin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.